Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG

- Loo, Sun, Roberts, Andrew W., Taper, John, Cull, Gavin, Tiley, Campbell, Verner, Emma, Hahn, Uwe, Hiwase, Devendra K., Iland, Harry J., Murphy, Nick, Ramanathan, Sundra, Reynolds, John, Anstee, Natasha S., Ong, DM, Tiong, IS, Wall, M, Murray, M, Rawling, T, Leadbetter, J, Rowley, L, Latimer, M, Yuen, SLS, Ting, SB, Kennedy, Glen A., Fong, CY, Morris, KL, Bajel, A, Seymour, JF, Levis, MJ, Wei, AH, He, Simon, Schwarer, Anthony P., Enjeti, Anoop K., D'Rozario, James, Marlton, Paula, Bilmon, Ian A.

Treatment outcomes of advanced hepatocellular carcinoma in real-life practice: Chemotherapy versus multikinase inhibitors

- Oranratnachai, Songporn, Rattanasiri, Sasivimol, Sirachainan, Ekaphop, Tansawet, Amarit, Raunroadroong, Nilubol, McKay, Gareth J., Attia, John, Thakkinstian, Ammarin

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with Carboplatin and Paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

- Hauschild, Axel, Agarwala, Sanjiv S, Peschel, Christian, Schadendorf, Dirk, Garbe, Claus, O'Day, Steven, Daud, Adil, White, J. Michael, Xia, Chenghua, Patel, Kiran, Kirkwood, John M., Keilholz, Ulrich, Trefzer, Uwe, Hogg, David, Robert, Caroline, Hersey, Peter, Eggermont, Alexander, Grabbe, Stephan, Gonzalez, Rene, Gille, Jens